Additional baricitinib loading dose improves clinical outcome in COVID-19

Pneumonia associated with coronavirus disease 2019 (COVID-19) has been accounted for high mortality rate in severe COVID-19 worldwide, and additional serious scarcity of standard and effective anti-inflammatory drug in COVID-19 pneumonia management is a big challenge. Baricitinib, a Janus kinase (JA...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hasan Md Jahidul, Rabbani Raihan, Anam Ahmad Mursel, Huq Shihan Mahmud Redwanul
Formato:	article
Lenguaje:	EN
Publicado:	De Gruyter 2020
Materias:	baricitinib covid-19 pneumonia loading dose maintenance dose Medicine R
Acceso en línea:	https://doaj.org/article/fa98f059064f41fa9868c28725b9263a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fa98f059064f41fa9868c28725b9263a
record_format	dspace
spelling	oai:doaj.org-article:fa98f059064f41fa9868c28725b9263a2021-12-05T14:10:53ZAdditional baricitinib loading dose improves clinical outcome in COVID-192391-546310.1515/med-2021-0010https://doaj.org/article/fa98f059064f41fa9868c28725b9263a2020-12-01T00:00:00Zhttps://doi.org/10.1515/med-2021-0010https://doaj.org/toc/2391-5463Pneumonia associated with coronavirus disease 2019 (COVID-19) has been accounted for high mortality rate in severe COVID-19 worldwide, and additional serious scarcity of standard and effective anti-inflammatory drug in COVID-19 pneumonia management is a big challenge. Baricitinib, a Janus kinase (JAK) inhibitor, is a promising drug in COVID-19 pneumonia. This study aims to compare the clinical outcome of moderate-to-severe COVID-19 pneumonia treated with baricitinib with or without a loading dose. This prospective case-control study enrolled 37 adult patients where 17 patients (control) received baricitinib at 4 mg oral daily dose and 20 patients (case) received an additional single 8 mg oral loading dose. The median day to gain blood oxygen saturation level ≥95% (in room air) and return in normal breathing function were lower in case group than the control group. The requirement of intensive care unit and mechanical ventilation support was higher in the control group than in the case group [29.4% (N = 17)/10% (N = 20), P < 0.05; 11.8% (N = 17)/5% (N = 20), P > 0.05), respectively]. Thus, an additional loading dose of baricitinib revealed better clinical outcome of patients with COVID-19 pneumonia.Hasan Md JahidulRabbani RaihanAnam Ahmad MurselHuq Shihan Mahmud RedwanulDe Gruyterarticlebaricitinibcovid-19 pneumonialoading dosemaintenance doseMedicineRENOpen Medicine, Vol 16, Iss 1, Pp 041-046 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	baricitinib covid-19 pneumonia loading dose maintenance dose Medicine R
spellingShingle	baricitinib covid-19 pneumonia loading dose maintenance dose Medicine R Hasan Md Jahidul Rabbani Raihan Anam Ahmad Mursel Huq Shihan Mahmud Redwanul Additional baricitinib loading dose improves clinical outcome in COVID-19
description	Pneumonia associated with coronavirus disease 2019 (COVID-19) has been accounted for high mortality rate in severe COVID-19 worldwide, and additional serious scarcity of standard and effective anti-inflammatory drug in COVID-19 pneumonia management is a big challenge. Baricitinib, a Janus kinase (JAK) inhibitor, is a promising drug in COVID-19 pneumonia. This study aims to compare the clinical outcome of moderate-to-severe COVID-19 pneumonia treated with baricitinib with or without a loading dose. This prospective case-control study enrolled 37 adult patients where 17 patients (control) received baricitinib at 4 mg oral daily dose and 20 patients (case) received an additional single 8 mg oral loading dose. The median day to gain blood oxygen saturation level ≥95% (in room air) and return in normal breathing function were lower in case group than the control group. The requirement of intensive care unit and mechanical ventilation support was higher in the control group than in the case group [29.4% (N = 17)/10% (N = 20), P < 0.05; 11.8% (N = 17)/5% (N = 20), P > 0.05), respectively]. Thus, an additional loading dose of baricitinib revealed better clinical outcome of patients with COVID-19 pneumonia.
format	article
author	Hasan Md Jahidul Rabbani Raihan Anam Ahmad Mursel Huq Shihan Mahmud Redwanul
author_facet	Hasan Md Jahidul Rabbani Raihan Anam Ahmad Mursel Huq Shihan Mahmud Redwanul
author_sort	Hasan Md Jahidul
title	Additional baricitinib loading dose improves clinical outcome in COVID-19
title_short	Additional baricitinib loading dose improves clinical outcome in COVID-19
title_full	Additional baricitinib loading dose improves clinical outcome in COVID-19
title_fullStr	Additional baricitinib loading dose improves clinical outcome in COVID-19
title_full_unstemmed	Additional baricitinib loading dose improves clinical outcome in COVID-19
title_sort	additional baricitinib loading dose improves clinical outcome in covid-19
publisher	De Gruyter
publishDate	2020
url	https://doaj.org/article/fa98f059064f41fa9868c28725b9263a
work_keys_str_mv	AT hasanmdjahidul additionalbaricitinibloadingdoseimprovesclinicaloutcomeincovid19 AT rabbaniraihan additionalbaricitinibloadingdoseimprovesclinicaloutcomeincovid19 AT anamahmadmursel additionalbaricitinibloadingdoseimprovesclinicaloutcomeincovid19 AT huqshihanmahmudredwanul additionalbaricitinibloadingdoseimprovesclinicaloutcomeincovid19
_version_	1718371638426206208

Additional baricitinib loading dose improves clinical outcome in COVID-19

Ejemplares similares